The Question
A 68-year-old man presents with 9 months of progressive exertional dyspnea and a dry cough. He is a former smoker (40 pack-year, quit 5 years ago). On exam he has resting oxygen saturation 95% on room air, bibasilar fine inspiratory crackles and digital clubbing. Pulmonary function testing shows FVC 65% predicted, FEV1/FVC ratio normal, and DLCO 45% predicted. Autoimmune serologies including ANA, rheumatoid factor, and anti-CCP are negative. High-resolution chest CT demonstrates basal predominant subpleural reticulation with honeycombing and traction bronchiectasis, no significant ground-glass opacities, no mosaic attenuation, and no mediastinal lymphadenopathy. There is no history of bird exposure, mold, or occupational inhalational exposures. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
A
Explanation
High-Yield Pearl: In an older patient with progressive dyspnea and an HRCT showing a definite usual interstitial pneumonia pattern (basal, subpleural honeycombing and traction bronchiectasis), a confident diagnosis of idiopathic pulmonary fibrosis can be made without surgical biopsy and antifibrotic therapy should be initiated to slow progression.
Detailed Reasoning: The imaging described is characteristic of a definite UIP pattern, which per ATS/ERS/JRS/ALAT guidelines permits a clinical diagnosis of IPF without surgical lung biopsy when other causes are reasonably excluded. Antifibrotic agents such as nintedanib or pirfenidone are guideline-recommended to reduce rate of FVC decline in IPF and are the preferred initial disease-specific therapy. High-dose corticosteroids are not effective for established fibrotic IPF and empiric immunosuppression can be harmful; the PANTHER trial demonstrated increased mortality and hospitalization with combination prednisone, azathioprine, and N-acetylcysteine. Surgical lung biopsy is reserved for patients with an indeterminate or alternative HRCT pattern where histopathology would change management; it is unnecessary and exposes patients to procedural risk when HRCT is definitive. Serum precipitin testing and antigen avoidance are important in suspected chronic hypersensitivity pneumonitis, but the CT pattern here lacks features of HP (no mosaic attenuation, no centrilobular nodularity, and no clear exposure), making HP less likely and antigen testing lower yield. Starting azathioprine with prednisone is specifically contraindicated in IPF due to demonstrated harm and is not guideline-recommended.
See you tomorrow morning!